16 Aug 2022 Novavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older
13 Aug 2022 Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants
09 Aug 2022 Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
03 Aug 2022 Vaxxinity’s Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non-Human Primates
28 Jul 2022 Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
26 Jul 2022 Bavarian Nordic Receives European Approval of Extension of Vaccine Label to Include Monkeypox
26 Jul 2022 FDA accepts HOOKIPA’s Investigational New Drug Application for HB-300 for the treatment of metastatic castration-resistant prostate cancer
22 Jul 2022 Blue Lake Biotechnology Announces First Participant Dosed in a Phase 1 Clinical Trial of Its BLB-201 Intranasal RSV Vaccine
21 Jul 2022 HilleVax Announces Results from 5-Year Clinical Study Supporting Long-Term Immunogenicity of HIL-214 Norovirus Vaccine Candidate
20 Jul 2022 Immunomic Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ITI-3000 pDNA Vaccine for the Treatment of Merkel Cell Carcinoma
14 Jul 2022 U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over
06 Jul 2022 Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant
29 Jun 2022 Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV
25 Jun 2022 Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate
25 Jun 2022 Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine
25 Jun 2022 Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001
24 Jun 2022 Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
23 Jun 2022 U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children
21 Jun 2022 Affinivax Presents Data for Enhanced Protection Against Serotype 3 in Next-Generation Pneumococcal Vaccine
21 Jun 2022 PharmaJet Partner, Nykode Therapeutics, Announces Positive Interim Results in HPV+ Cervical Cancer Phase 2 Trial
21 Jun 2022 Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults
20 Jun 2022 Ultimovacs’ UV1 cancer vaccine shows strong overall survival in malignant melanoma phase I trial
13 Jun 2022 Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron
11 Jun 2022 GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults
06 Jun 2022 GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up